Oliver Sartor
Papers
1
Total Citations
5
H-Index
1
About
Dr. Oliver Sartor is a leading oncologist whose research has fundamentally shaped the treatment of prostate cancer, particularly through his pioneering work in radiopharmaceuticals and hormonal therapies. He is best known for his central role in the development of Lutetium-177-PSMA-617 (Pluvicto), a targeted radioligand therapy that has revolutionized care for men with metastatic castration-resistant prostate cancer. Dr. Sartor led the pivotal VISION trial, which demonstrated a significant survival benefit for this therapy, establishing a new standard of care and earning him global recognition. His contributions extend to the study of androgen receptor inhibitors and novel biomarkers, with his work collectively amassing over 50,000 citations. A prolific author and principal investigator, Dr. Sartor has also been instrumental in advancing immunotherapy combinations and understanding treatment resistance. His relentless focus on translating laboratory discoveries into life-extending treatments has made him one of the most influential figures in genitourinary oncology, directly improving outcomes for countless patients worldwide.
Research Focus
Key Achievements
Top Papers
- 1